Skip to main content

Advertisement

SpringerLink
Log in

Pembrolizumab for primary malignant melanoma of the central nervous system

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Whiteman DC, Pavan WJ, Bastian BC (2011) The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigm Cell Melanoma Res 24(5):879–897

    Article  CAS  Google Scholar 

  2. Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, Esplin BL, Dronca RS (2016) The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res 26(3):300–303

    Article  PubMed  CAS  Google Scholar 

  3. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havek JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We thank Arnault de la Fouchardière, MD, PhD (Department of Biopathology, Centre Leon Berard, Lyon) for his work on the molecular analysis.

Author information

Authors and Affiliations

  1. Department of Dermatology, Centre hospitalier Régional Orléans La Source, 14 Avenue de l’Hôpital, CS 86709, 45067, Orléans Cedex 2, France

    Chakib El Habnouni & Guido Bens

  2. Department of Pathology, Centre hospitalier Régional Orléans La Source, 14 Avenue de l’Hôpital, CS 86709, 45067, Orléans Cedex 2, France

    Claire Bléchet

Authors
  1. Chakib El Habnouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claire Bléchet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guido Bens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chakib El Habnouni.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Research involving human and animals participants

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Habnouni, C., Bléchet, C. & Bens, G. Pembrolizumab for primary malignant melanoma of the central nervous system. J Neurooncol 139, 225–227 (2018). https://doi.org/10.1007/s11060-018-2848-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-018-2848-y

Search

Navigation